NASDAQ:FTSVForty Seven Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Forty Seven Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $95.51 0.00 (0.00 %) (As of 04/7/2020) Add Compare Share Today's Range$95.51Now: $95.51▼$95.5150-Day Range$95.51MA: $95.51▼$95.5152-Week Range$5.53Now: $95.51▼$95.51VolumeN/AAverage Volume1.61 million shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/ABeta0.4 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingForty Seven has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 4 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.95, Forty Seven has a potential downside of 30.9% from its current price of $95.51.Amount of Analyst CoverageForty Seven has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesForty Seven has received 141 “outperform” votes. (Add your “outperform” vote.)Underperform VotesForty Seven has received 132 “underperform” votes. (Add your “underperform” vote.)Community SentimentForty Seven has received 51.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote “Outperform” if you believe FTSV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldForty Seven does not currently pay a dividend.Dividend GrowthForty Seven does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forty Seven insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,499,733.00 in company stock.Percentage Held by Insiders37.40% of the stock of Forty Seven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.77% of the stock of Forty Seven is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Forty Seven are expected to decrease in the coming year, from ($3.04) to ($3.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forty Seven is -38.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forty Seven is -38.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForty Seven has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FTSV Previous Symbol CUSIPN/A CIKN/A Webwww.fortyseveninc.com Phone650-352-4150Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.68 million Price / Sales293.33 Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book12.70Profitability EPS (Most Recent Fiscal Year)($2.34) Net Income$-87,620,000.00 Net MarginsN/A Return on Equity-50.38% Return on Assets-44.35%Miscellaneous Employees57 Outstanding Shares48,156,000Market Cap$4.60 billion Next Earnings DateN/A OptionableNot Optionable NASDAQ:FTSV Rates by TradingView Receive FTSV News and Ratings via Email Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter. Forty Seven (NASDAQ:FTSV) Frequently Asked Questions How has Forty Seven's stock been impacted by COVID-19 (Coronavirus)? Forty Seven's stock was trading at $94.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FTSV shares have increased by 0.9% and is now trading at $95.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Forty Seven? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Forty Seven. How were Forty Seven's earnings last quarter? Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings results on Friday, March, 20th. The company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.70) by $0.15. View Forty Seven's earnings history. What price target have analysts set for FTSV? 11 brokers have issued twelve-month price objectives for Forty Seven's stock. Their forecasts range from $18.00 to $95.50. On average, they expect Forty Seven's stock price to reach $65.95 in the next year. This suggests that the stock has a possible downside of 30.9%. View analysts' price targets for Forty Seven. What are Wall Street analysts saying about Forty Seven stock? Here are some recent quotes from research analysts about Forty Seven stock: 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (3/27/2020) 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019) Has Forty Seven been receiving favorable news coverage? News articles about FTSV stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Forty Seven earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutForty Seven. Who are some of Forty Seven's key competitors? Some companies that are related to Forty Seven include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Dr.Reddy's Laboratories (RDY) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Forty Seven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), NVIDIA (NVDA), Amarin (AMRN), GlycoMimetics (GLYC), Trillium Therapeutics (TRIL), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Clovis Oncology (CLVS). Who are Forty Seven's key executives? Forty Seven's management team includes the following people: Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)Mr. Mark Chao, Founder & VP of Clinical Devel.Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel. When did Forty Seven IPO? (FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers. What is Forty Seven's stock symbol? Forty Seven trades on the NASDAQ under the ticker symbol "FTSV." Who are Forty Seven's major shareholders? Forty Seven's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.82%), Wellington Management Group LLP (4.38%), Pentwater Capital Management LP (3.10%), JPMorgan Chase & Co. (3.03%), Beryl Capital Management LLC (2.33%) and Magnetar Financial LLC (1.77%). Company insiders that own Forty Seven stock include Ann D Rhoads, Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View institutional ownership trends for Forty Seven. Which major investors are selling Forty Seven stock? FTSV stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Healthcare of Ontario Pension Plan Trust Fund, Lord Abbett & CO. LLC, Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, Schroder Investment Management Group, Deutsche Bank AG, and Rock Springs Capital Management LP. Company insiders that have sold Forty Seven company stock in the last year include Ann D Rhoads, Chris H Takimoto, Irving Weissman, Mark Anthony Mccamish, and Ravindra Majeti. View insider buying and selling activity for Forty Seven. Which major investors are buying Forty Seven stock? FTSV stock was acquired by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, JPMorgan Chase & Co., Beryl Capital Management LLC, Magnetar Financial LLC, Alpine Associates Management Inc., Glazer Capital LLC, ARP Americas LP, and CNH Partners LLC. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Peter Nieh, Ravi Mhatre, and Stefan A Dyckerhoff. View insider buying and selling activity for Forty Seven. How do I buy shares of Forty Seven? Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Forty Seven's stock price today? One share of FTSV stock can currently be purchased for approximately $95.51. How big of a company is Forty Seven? Forty Seven has a market capitalization of $4.60 billion and generates $15.68 million in revenue each year. The company earns $-87,620,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Forty Seven employs 57 workers across the globe. What is Forty Seven's official website? The official website for Forty Seven is www.fortyseveninc.com. How can I contact Forty Seven? Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
